CellCentric has a dominant discovery platform in epigenetics based on the active management of an unparalleled worldwide network of over 20 leading researchers at major Institutions. CellCentric is uniquely able to prioritize new targets for the development of small molecule therapeutics.

The company has multiple discovery and development programmes across a range of enzyme classes, including demethylases, methyltransferases and ubiquitin modulators.